摘要
目的探讨低分子肝素治疗孕足月病理性高凝状态的有效性和安全性。方法选取本院分娩D-聚体高于参考值的孕产妇160例并分为治疗组和对照组,每组80例。治疗组予低分子肝素钙4 100 U皮下注射,1次/d,7 d为一个疗程;对照组不予抗凝治疗。同时监测7 d低分子肝素应用后、术后/产后2 d的凝血功能、D-二聚体值及血常规、妊娠及围产儿结局。结果低分子肝素能明显降低血液高凝状态,能使围生期病理性高凝状态转变为生理性高凝状态,从而降低VTE及DIC的发病率。结论低分子肝素钙能安全有效地预防并治疗孕妇病理性高凝状态,值得临床推广应用。
Objective To explore the safety and efficacy of low molecular heparin in the treatment of fullterm pregnant women with pathological hypercoagulabale stage. Methods 160 pregnant women with over standard level of Ddimer were divided into treatment group and control group, 80 cases in each group. The treatment group was treated with low molecular heparin calcium 4 100 U by subcutaneous injection once per day, 7 days were considered as a course of treatment. The control group was not conducted with anticoagulant therapy. Coagulation function, Ddimers and blood routine, pregnancy and perinatal outcome were monitored at the time points of 7 days after application of low molecular heparin and two days after spontaneous delivery or operation. Results Low molecular heparin could significantly improve hematological hypercoagulabale stage, and it is able to make the perinatal pathological hypercoagulabale stage transform to normal hypercoagulabale stage in order to reduce the incidence rate of VTE and DIC. Conclusion Low molecular heparin can prevent and treat the perinatal pathological hypercoagulabale stage effectively in full - term pregnant women, so it is worthy of clinical application.
出处
《实用临床医药杂志》
CAS
2014年第5期139-141,共3页
Journal of Clinical Medicine in Practice
关键词
低分子肝素
孕足月
病理性高凝状态
生理性高凝状态
low molecular heparin
full - term pregnancy
hypercoagulabale stage
physiological hypercoagulabale stage
